Effects of CXCR1/2 Blockade with Ladarixin on Streptozotocin-Induced Type 1 Diabetes Mellitus and Peripheral Neuropathy and Retinopathy in Rat (Diabetes Metab J 2025;49:990-1005)

Serena Boccella; Andrea Maria Morace; Cristina Giorgio; Francesca Guida; Michela Perrone; Iolanda Manzo; Carmela Belardo; Meghan Jones; Sabatino Maione; Andrea Aramini; Marcello Allegretti; Livio Luongo; Laura Brandolini

doi:10.4093/dmj.2026.0036

Articles

Page Path: HOME > Diabetes Metab J > Volume 50(3); 2026 > Article

Response Effects of CXCR1/2 Blockade with Ladarixin on Streptozotocin-Induced Type 1 Diabetes Mellitus and Peripheral Neuropathy and Retinopathy in Rat (Diabetes Metab J 2025;49:990-1005): Serena Boccella^1*, Andrea Maria Morace^2*, Cristina Giorgio^1*, Francesca Guida², Michela Perrone², Iolanda Manzo², Carmela Belardo², Meghan Jones³, Sabatino Maione², Andrea Aramini⁴, Marcello Allegretti⁴, Livio Luongo², Laura Brandolini⁴; Diabetes & Metabolism Journal 2026;50(3):626-627.
DOI: https://doi.org/10.4093/dmj.2026.0036
Published online: April 30, 2026

418 Views
12 Download

¹Research & Early Development (R&D), Dompé Farmaceutici SpA, Naples, Italy

²Pharmacology Division, Department of Experimental Medicine, University of Campania “L. Vanvitelli”, Naples, Italy

³R&D, Dompé US, San Mateo, CA, USA

⁴R&D, Dompé Farmaceutici SpA, L’Aquila, Italy

Corresponding author: Laura Brandolini

R&D, Dompé Farmaceutici SpA, Via Campo di Pile, L’Aquila 67100, Italy E-mail: Laura.Brandolini@dompe.com

*Serena Boccella, Andrea Maria Morace, and Cristina Giorgio contributed equally to this study as first authors.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Full Article

Download PDF

NOTES
REFERENCES
About this article

See the letter "Effects of CXCR1/2 Blockade with Ladarixin on Streptozotocin-Induced Type 1 Diabetes Mellitus and Peripheral Neuropathy and Retinopathy in Rat" on page 990.

We are pleased to submit the revised version of our manuscript entitled ‘Effects of CXCR1/2 blockade with ladarixin on streptozotocin-induced type 1 diabetes mellitus and peripheral neuropathy and retinopathy in rat’ for consideration in Diabetes & Metabolism Journal [1].

We sincerely thank the reviewers and Dr. Sheng Chen for their thoughtful and insightful comments regarding our study. We have carefully considered the suggestions and have provided detailed responses in our accompanying point-by-point reply. Specifically, we have addressed the questions concerning:

1. Differential regulation of CXC motif chemokine receptor 1/2 (CXCR1/2): We acknowledge the importance of distinguishing receptor-specific effects in the diabetic retina. While the current dataset does not allow definitive conclusions, we have emphasized the need for future cell-type–specific analyses and clarified this in the manuscript discussion.

2. Dose–response analyses and nerve fiber specificity: We agree that translational interpretation requires functional assessments of small versus large nerve fibers. We have highlighted plans for future studies incorporating advanced ocular imaging (e.g., optical coherence tomography angiography) and electrophysiological testing to assess functional outcomes.

We believe these revisions strengthen the manuscript and clarify the clinical relevance and potential mechanistic insights of ladarixin in diabetic complications.

We appreciate the constructive guidance provided, which has been invaluable in refining our discussion and the presentation of our findings. We hope the revisions meet the expectations of the reviewers and the editorial team and look forward to your favorable consideration.

Thank you for your time and attention.

NOTES

CONFLICTS OF INTEREST

Serena Boccella, Cristina Giorgio, Andrea Aramini, Marcello Allegretti, Meghan Jones, and Laura Brandolini are Dompé Farmaceutici SpA employees and Andrea Maria Morace, Francesca Guida, Michela Perrone, Iolanda Manzo, Carmela Belardo, Sabatino Maione, and Livio Luongo are University of Vanvitelli in Naples employees. The authors declare no competing interests in relation to the contents of this work. The authors declare that this study received funding from Dompé Farmaceutici SpA.

REFERENCES

1. Boccella S, Morace AM, Giorgio C, Guida F, Perrone M, Manzo I, et al. Effects of CXCR1/2 blockade with ladarixin on streptozotocin-induced type 1 diabetes mellitus and peripheral neuropathy and retinopathy in rat. Diabetes Metab J 2025;49:990-1005.PubMed PMC

Figure & Data

References

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Effects of CXCR1/2 Blockade with Ladarixin on Streptozotocin-Induced Type 1 Diabetes Mellitus and Peripheral Neuropathy and Retinopathy in Rat (Diabetes Metab J 2025;49:990-1005)

Diabetes Metab J. 2026;50(3):626-627. Published online April 30, 2026

DOI: https://doi.org/10.4093/dmj.2026.0036

XML Download

Related articles

Effects of CXCR1/2 Blockade with Ladarixin on Streptozotocin-Induced Type 1 Diabetes Mellitus and Peripheral Neuropathy and Retinopathy in Rat (Diabetes Metab J 2025;49:990-1005)

About this article

Boccella S, Morace AM, Giorgio C, Guida F, Perrone M, Manzo I, Belardo C, Jones M, Maione S, Aramini A, Allegretti M, Luongo L, Brandolini L. Effects of CXCR1/2 Blockade with Ladarixin on Streptozotocin-Induced Type 1 Diabetes Mellitus and Peripheral Neuropathy and Retinopathy in Rat (Diabetes Metab J 2025;49:990-1005). Diabetes Metab J. 2026;50(3):626-627.

DOI: https://doi.org/10.4093/dmj.2026.0036.

Download citation ↓